Amplitude Venture Capital — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
Mediar Therapeuticsmediartx.cominSeries B · Jan 2026 · $76M
Mediartx develops novel therapies for patients with fibrotic diseases.
BiotechMedical DevicesBoston, US
Rahul Ballal, PhD(CEO)Paul Yaworsky, PhD(CSO)inRahul Ballal(Executive Officer, Director)inBrian Hubbard(Director)Stacey Brenner(Executive Officer)David de Graaf(Director)
Co-investorsAgent CapitalLongwood FundMission BiocapitalNovartis Venture FundOno Venture Investment, Inc.Pfizer Venture Investments+3 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.